This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
by Sundeep Ganoria
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $41.66, marking a +0.6% move from the previous day.
5 Stocks That Powered S&P 500 ETF in Trump's First Week
by Sweta Killa
The S&P 500 logs the best first week of a presidential term in four decades. Here are five stocks in the ETF that led the gains.
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy launch progresses.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Company News for Jan 22, 2025
by Zacks Equity Research
Companies In The Article Are:MRNA, WBA, FITB and PLD
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
by Zacks Equity Research
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
How to Play Moderna Stock After the Recent Sales Guidance Cut
by Sundeep Ganoria
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
by Zacks Equity Research
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
by Kinjel Shah
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $34.45, representing a -1.98% change from its previous close.
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash
by Zacks Equity Research
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.
Company News for Jan 14, 2025
by Zacks Equity Research
Companies in The News Are: MRNA, NVDA, HP, NYC
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death
by Sundeep Ganoria
The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
by Zacks Equity Research
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Company News for Jan 8, 2025
by Zacks Equity Research
Companies In The News Are: RPM, LNN, TSLA, MRNA.
Moderna (MRNA) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day.
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
Merck to End Development of Two Cancer Candidates: Time to Sell?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Stock Market News for Dec 18, 2024
by Zacks Equity Research
Wall Street closed lower on Tuesday, eagerly awaiting the Fed meeting.
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
by Zacks Equity Research
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
by Kinjel Shah
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
by Zacks Equity Research
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.